MedWatch

Genmab technology to put pressure on copyists

The most recent technology from Genmab, the so-called HexaBody platform, could play a significant role in Big Pharma’s battle against generics manufacturers in the future, says the company’s CEO.

Expectations are great for the HexaBody platform, designed to increase the effect of antibody treatments. Current blockbusters, and even abandoned candidate drugs, could turn out to be a future goldmine for the Danish developer of the technology, Genmab.

“In the future we will see a society that is only willing to pay for the very best products, and that’s why our HexaBody platform is so important. You see candidate drugs failing more or less on a daily basis, and it has been like that for a long time,” Genmab CEO, Jan van de Winkel, tells Medwatch. He elaborates:

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier